IPO - Profile


We are a genetic medicines company pioneering a new approach to the care of cardiovascular disease, or CVD, transforming treatment from chronic management to single-course gene editing medicines. Despite advances in treatment over the last 50 years, CVD remains the leading cause of death worldwide. The current paradigm of chronic care is fragile—requiring rigorous patient adherence, extensive healthcare infrastructure and regular healthcare access—and leaves many patients without adequate care.

Our goal is to disrupt the chronic care model for CVD by providing a new therapeutic approach with single-course in vivo gene More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$19.00 14,000,000 Positive High 29.78%

Offering Team

  • Legal counsel
  • Wilmer Cutler Pickering Hale and Dorr LLP
  • Auditors
  • Ernst & Young LLP

Deal Highlights

Deal Tracker

IPO Dates

Filing 16 Jun, 2021

Offer 17 Jun, 2021

Look Ahead

Lock Up Expiry Dec 17, 2021

IPO Terms

Offer Price $19.00
Offer Size 14M

Market Sentiments

Stock Price